The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock

The drugmaker is heavily discounting its immune-disease drug Humira to protect market share this year.

WSJ News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira

pharmaceutical company ABV Inc. is looking for its next hit. Now its blockbuster immune-disease therapy Humira…

Disney, Pepsi, Uber Set to Report During Lackluster Earnings Season

Business Income Fewer companies than usual are beating Wall Street estimates

U.S. Appeals Court Sides With Drugmakers on Discount Program

Business Health care Health Drug makers can limit shipments to hospitals and clinics of drugs subsidized…

Johnson & Johnson Fourth-Quarter Earnings Down 25%

The healthcare-products company reported a fourth-quarter sales decline as demand for its COVID-19 vaccine declined.

opinion | The West’s Drug-Price Self-Sabotage

A lesson from Europe to the US on how price controls reduce access to treatment and…

When Executives Stop Selling Stock, a Big Deal Might Be Ahead

Market deal Stagnation in insider selling may be a clue for investors, past bids show

WSJ News Exclusive | Moderna Considers Price of $110-$130 for Covid-19 Vaccine

WSJ News Exclusive Health Commercial value similar to Pfizer’s plans after government contract ends

AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including the rights to…

Investors’ Best Friend in 2022: The Dogs of the Dow

The 10 highest dividend yielding stocks of the Dow components gained 2.2% at the beginning of…